國家衛生研究院 NHRI:Item 3990099045/12263
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 862624      線上人數 : 692
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12263


    題名: Chemo-radiotherapy in adjuvant therapy of curatively resected pancreatic cancer: Lesions from TCOG T3207 study
    作者: Chen, LT
    貢獻者: National Institute of Cancer Research
    摘要: In contrast to the established role of adjuvant chemotherapy, the benefit of adjuvant chemoradiation (CRT) in resectable PDAC remain controversial. In the absence of level I-II evidence, the ESMO guideline recommends, no CRT should be given to patients after surgery except in clinical trials, while the latest NCCN and ASCO guidelines included adjuvant radiotherapy or CRT as part of integrated therapy following adjuvant chemotherapy in patients who did not receive preoperative therapy and had R1 resection margins or N1 disease. TCOG T3207 study is the first reported randomized trial that was designed to evaluate the role of CRT in patients with resectable PDAC receiving standard six cycles of adjuvant gemcitabine. Despite associated with marginal benefit in reducing loco-regional recurrence (54.1% versus 38.4%, p=0.056), the addition of CRT did not improve the recurrence-free survival (RFS, primary end-point), median RFS: 13.3 months (95% CI 10.0-17.1) versus 12.1 months (95% CI, 9.0-15.8) in GEM alone arm, HR=0.96 (p= 0.80), in patients with resectable PDAC receiving adjuvant gemcitabine. What will be the potential role of CRT in more modern multi-agent adjuvant therapy, such as modified FOLFIRINOX will be discusse
    日期: 2019-10
    關聯: Annals of Oncology. 2019 Oct;30(Suppl. 6):75.
    Link to: http://dx.doi.org/10.1093/annonc/mdz354
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000491239300384
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000491239300384.pdf71KbAdobe PDF239檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋